Company
APT
TRANSFORMING HUMAN APYRASE INTO LIFE SAVING MEDICINE
Also known as APT Therapeutics
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Headquarters
- St Louis, Missouri, United States
- Founded
- 2001
- Customers
- pharma partners
Claim, correct or request removal
Record updated 18 September 2026
About
APT Therapeutics™ is developing optimized human apyrases as safe, effective, and cost-competitive antiplatelet therapy for acute myocardial infarction, stroke and transplantation complications.
Funding snapshot
- Total raised
- $1.6MSum of rounds, as of 2026-09-18Source (opens in a new tab)
- Latest round
- Seed, $1.6M2002-06-03
Funding rounds
- Seed
- $1.6M2002-06-03, Company stated
Products
- Other
- APT-102
Loading relationship preview